Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the <i>BRCA1/2</i> Mutation

Jung, Soon‐Moon; Ryu, Jai Min; Park, Hyung Seok; Park, Ji Soo; Kang, Eunyoung; Lee, Seeyoun; Lee, Han‐Byoel; Youn, Hyun Jo; Yoo, Tae-Kyung; Kim, Jisun; Lee, Jeong Eon; Han, Seok Joo; Kim, Dong-Won; Kim, Sung-Won

doi:10.4048/jbc.2020.23.e61

Cited by 13 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this paper, the proportion of BRCA mutation‐positive patients with a history of breast cancer who underwent RRSO was 100% at two of the 18 facilities, while it was less than only 15% at three facilities 18 . This data showed that even in South Korea, there was a large difference in awareness of RRSO among hospitals 18 . These data from South Korea imply that the difference in awareness of RRSO between facilities may rise in Japan since RRSO was covered with public health insurance in Japan only a year ago.…”

Section: Discussion On Issues Surrounding Rrso In Japanmentioning

confidence: 75%

A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk‐reducing surgery for hereditary breast and ovarian cancer

Hirayama

Inayama

Odajima

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

At the 73rd Annual Congress of the Japan Society of Obstetrics and Gynecology, young doctors from Japan and South Korea made presentations on the present condition of risk‐reducing surgery for hereditary breast and ovarian cancer (RRSO) in their respective country. RRSO was insured in Japan in April 2020, whereas in South Korea, it was insured 7 years earlier in 2013. In Japan, certification criteria have been set for facilities that perform RRSO, and the number of facilities is increasing, but regional disparities still exist in its distribution. The number of gBRCA1/2 testing facilities is larger, and the cost is more affordable in South Korea than in Japan. Additionally, South Korea provides genetic counseling to a wider range of relatives compared to Japan. In the future, as the indications for the gBRCA1/2 test have expanded as a companion diagnostic for the use of PARP inhibitors, it is expected that the number of candidates for the gBRCA1/2 mutation test and RRSO will increase in Japan. It is important to increase the number of BRCA tests while maintaining the quality of genetic counseling in order to provide adequate information on BRCA mutations and RRSO for patients to support their decision. For the development of hereditary breast and ovarian cancer (HBOC) medical care, it is necessary to publish a nationwide database in Japan and continue to analyze and discuss the data based on the results.

show abstract

Section: Discussion On Issues Surrounding Rrso In Japanmentioning

confidence: 75%

A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk‐reducing surgery for hereditary breast and ovarian cancer

Hirayama

Inayama

Odajima

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Until recently, the tests were performed primarily in patients with a strong family history of cancer and involved a limited number of genes known to be associated with a high risk of cancer or with specific cancer syndromes. With the advent of affordable sequencing, testing with larger gene panels has become possible [80][81][82]. The risk ratios for BC associated with variants in BRCA-1/2 are quite different (10.6 and 5.9, respectively) and correspond to lifetime risks of 55 and 45%, the cumulative risk of MC at 80 years of age it was 72% (95% Confidence Interval [CI], 65 to 79) for BRCA-1 carriers [81].…”

Section: Discussionmentioning

confidence: 99%

“…Population estimates of breast cancer risk associated with germline pathogenic variants in cancer predisposition genes are critically needed for risk assessment and treatment in women with inherited pathogenic variants. These estimates may inform cancer screening and testing and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes [20,[80][81][82]].…”

Section: Discussionmentioning

confidence: 99%

“…When an mastography is performed, it is recommended to consider tomosynthesis, as in BRCA-1/2 carriers, breast MRI is preferred in women under 30 years of age to mastography due to the potential risk of radiation exposure and lower sensitivity for the BM detection. There are no data on risk reduction surgery in women with LFS, the options for risk reducing mastectomy are individual; include discussion of cancer risk reduction / protection, risks associated with surgery, age-specific degree of cancer risk, reconstructive options, and competing risks of other cancers; family history and life expectancy should be considered during this counseling[80]. index of suspicion for second malignancies in cancer survivors and rare cancers.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Genetics of Breast and Ovary Cancers Associated with Hereditary Cancers and their Clinical Management

Hernández¹,

Vvh²

2021

COO

View full text Add to dashboard Cite

1.1. Background: Carriers of the BRCA-1/2 mutation have increased and variable risks of Breast Cancer (BC) and ovarian cancer and vary or are modified by common genetic variants and their incidence genetic testing and risk-reducing surgery has increased, they should receive advice and evaluation by the physician with experience in genetics 1.2. Objective: The genetics of BRCA-1/2 gene mutations and their impact on women have been reviewed. Methods:We reviewed the publications in PubMed, Web of Science, Scopus, related to mutations of the BRCA-1/2 genes and hereditary cancers, to assess prevention, detection and management and how to improve quality of life 1.3. Results: increased use was identified of tests, as well as risk-reducing surgery, the use of new screening strategies; Still, there is no effective detection protocol that has been shown to reduce mortality, only risk-reducing surgery, such as mastectomy and bilateral salpingo-oophorectomy; recommended after parity satisfied, has improved chemoprevention and reproductive capacity. Conclusions:Identification of women who carry a pathogenic mutation in high-risk BRCA-1/2 genes; the clinical management, prevention and identification of related cancers improves the morbidity and mortality of these patients of their individual risk clinicsofoncology.com

show abstract

“…In South Korea, since medical coverage for BRCA1/2 screening test by the National Health Insurance system started in 2012 and with the rise of the Angelina Jolie effect, the popularity of BRCA1/2 gene testing and prophylactic management has increased. The number of contralateral mastectomy and salpingooophorectomy for prophylactic purposes among breast cancer patients with BRCA1/2 mutations has also increased [8,9]. Given the increased awareness, insurance coverage for genetic testing, and advancements in genetic testing technologies [8,10], the perceptions of and attitudes to risk-reducing surgeries need to be assessed not only for BRCA1/2 carriers or breast cancer patients with a family history of cancer but also for generally healthy women.…”

Section: Introductionmentioning

confidence: 99%

Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea

Park

Kim

et al. 2022

Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

This study investigated the attitudes toward risk-reducing mastectomy (RRM) and riskreducing salpingo-oophorectomy (RRSO) as cancer prevention options for BRCA1/2 carriers in healthy, young, unmarried Korean women. Materials and MethodsA nationally representative sample of 600 women, aged 20-39 years, completed a questionnaire on sociodemographic variables, preference for genetic testing, and intention to undergo risk-reducing surgeries after receiving information on the cancer risk of BRCA1/2 mutations and benefits of risk-reducing surgeries. ResultsA total of 54.7% and 57.7% had the intention to undergo RRM and RRSO, respectively, on the assumption that they were BRCA1/2 carriers. Older age and no intention to undergo genetic testing were associated with a reduced likelihood of undergoing RRM (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.14 to 0.61 for age 35-39 years and OR, 0.35; 95% CI, 0.20 to 0.62 for no intention for genetic testing) and RRSO (OR, 0.39; 95% CI, 0.19 to 0.79 for age 35-39 years and OR, 0.30; 95% CI, 0.17 to 0.53 for no intention for genetic testing). Women who chose to be single were likely to undergo risk-reducing surgeries (OR, 1.67; 95% CI, 1.07 to 2.60 for RRM and OR, 1.56; 95% CI, 1.00 to 2.44 for RRSO). ConclusionMore than 50% of healthy, unmarried, young Korean women were inclined to undergo prophylactic surgeries if they were BRCA1/2 mutation carriers. Further studies on decisionmaking process for cancer prevention in individuals at high risk for cancer need to be conducted.

show abstract

Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation

Cited by 13 publications

References 26 publications

A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk‐reducing surgery for hereditary breast and ovarian cancer

A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk‐reducing surgery for hereditary breast and ovarian cancer

Genetics of Breast and Ovary Cancers Associated with Hereditary Cancers and their Clinical Management

Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea

Contact Info

Product

Resources

About